Mr. Wei Zhang is a Professor of Clinical Pharmacology at Central South University, China. He earned his Ph.D. in Pharmacology in 2006 under Prof. Hong-Hao Zhou. With expertise in pharmacogenomics, drug metabolism, and clinical trials, he has led major research projects, including personalized therapy and pharmacogenomic studies in diabetes. Zhang has served as Associate Dean of the Institute of Clinical Pharmacology and has been recognized with prestigious awards like the โNew Century Excellent Talentsโ and โHenry Fok Young Teacher Award.โ His research has significantly influenced precision medicine, enhancing drug efficacy and safety through genetic insights.
AUTHOR PROFILE
Scopus Profile
Orcid Profile
๐EARLY ACADEMIC PURSUITS:
Mr. Wei Zhang embarked on his academic journey at Central South University, China. He demonstrated a strong commitment to pharmacology and clinical medicine from an early stage:
- Ph.D. in Pharmacology (2003-2006) โ Under the supervision of Prof. Hong-Hao Zhou, a distinguished member of the China Engineering Academy, he specialized in clinical pharmacology, drug assay, pharmacokinetics, and pharmacodynamics.
- M.A. in Pharmacology (2001-2003) โ Focused on clinical pharmacology and pharmacogenomics, with practical expertise in human DNA pyrosequencing and drug metabolism.
- B.A. in Clinical Medicine (1996-2001) โ Gained foundational knowledge in pharmacology, physiology, pathology, and clinical medicine at XiangYa Medical School.
๐
PROFESSIONAL ENDEAVORS:
Throughout his career, Mr. Zhang has held significant academic and administrative roles at Central South University, contributing to the advancement of clinical pharmacology:
- Professor (2013-Present) โ Department of Clinical Pharmacology, Central South University.
- Associate Dean (2009-Present) โ Institute of Clinical Pharmacology.
- Visiting Scholar (2012-2013) โ University of Maryland, USA, exploring cutting-edge pharmaceutical research.
- Head of Genetic Testing Laboratory (2007-2013) โ Pioneered pharmacogenomic analysis.
- Associate Professor (2008-2013) & Lecturer (2006-2008) โ Focused on research and teaching in pharmacology.
- Scientific Secretary (2005-Present) โ National Key Discipline of Pharmacology, managing national-level research initiatives.
๐ฌCONTRIBUTIONS AND RESEARCH FOCUS ON PHARMACOLOGY:
Mr. Zhang has led groundbreaking pharmacogenomics research, focusing on drug metabolism, personalized medicine, and renal drug toxicity. He has been a Principal Investigator (PI) in numerous national projects, including:
- Pharmacogenomics Research on Type 2 Diabetes (2016-2019) โ National Natural Science Foundation of China.
- Multidrug Resistance Protein 2 (MRP2) & Cisplatin Nephrotoxicity (2013-2015) โ Investigating genetic variations affecting renal drug accumulation.
- Personalized Therapy via Pharmacogenetic Biomarkers (2012-2016) โ National High Technology Research & Development Program (863 Program).
- OATP1B1 Modulators & Mechanisms (2009-2011) โ Studied drug transport mechanisms in human liver cells.
- Pharmacogenomics in Drug Development (2009-2010) โ Contributed to the national push for innovative drug research in China.
๐IMPACT AND INFLUENCE:
As a global thought leader, Mr. Zhang has actively participated in international conferences and academic collaborations, including:
โ
Keynote Speaker & Presenter at pharmacogenetics conferences in China, Korea, Hong Kong, and the USA.
โ
Chairperson at the Cross-Strait Symposium on Pharmacogenomics (2012).
โ
Presenter at AAPS Annual Meeting (2013, USA).
โ
Collaborations with leading global research institutions.
His research has significantly influenced precision medicine and drug safety protocols, enhancing clinical trial methodologies worldwide.
๐ACADEMIC CITES AND RECOGNITION:
Mr. Zhang’s academic excellence has been recognized through numerous awards and scholarships:
Class I Scholarship, Central South University (2004, 2005).
Outstanding Postgraduate Student Award (2004, 2005).
Excellent Report Award, Chinese Pharmacological Society (2005).
Outstanding Graduate of Central South University (2006).
“New Century Excellent Talents” Award, Ministry of Education (2010).
Science & Technology Prize, Chinese Society of Pharmacy (2010).
China Scholarship Council Foreign Fund (2012).
Outstanding Young Talents Award, China (2013).
Henry Fok Young Teacher Award (2014).
These accolades underscore his significant contributions to pharmacology and clinical research.
๐ฎLEGACY AND FUTURE CONTRIBUTIONS:
Mr. Zhang’s pioneering research in pharmacogenomics and clinical pharmacology has laid a strong foundation for:
- Advancements in Personalized Medicine โ Tailoring drug therapies based on genetic profiles.
- Improved Drug Safety & Efficacy โ Minimizing adverse drug reactions through genomic insights.
- Mentorship & Academic Leadership โ Training the next generation of pharmacologists and medical researchers.
- Innovative Drug Development Strategies โ Enhancing China’s pharmaceutical industry through precision medicine.
His vision for the future includes expanding global collaborations, leveraging AI in pharmacogenomics, and fostering next-generation clinical trials to revolutionize drug development and patient care.
๐CONCLUSION:
Mr. Wei Zhang has made remarkable contributions to the field of clinical pharmacology and pharmacogenomics. His extensive research on personalized medicine, drug metabolism, and genetic biomarkers has advanced precision medicine, improving drug efficacy and safety. As a dedicated educator, researcher, and leader, he has mentored future scientists while holding key academic positions. His impactful work continues to shape the future of pharmacological research and healthcare innovation. With numerous accolades and groundbreaking studies, his legacy will inspire generations to come, driving advancements in drug development and individualized therapy.
TOP NOTABLE PUBLICATIONS
Title: The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals
Authors: L. Wang, B. Yu, Y. Peng, H. Zhou, J. Yin
Journal: Innovation
Year: 2025
Title: Astragali Radix-Angelicae Sinensis Radix inhibits the activation of vascular adventitial fibroblasts and vascular intimal proliferation by regulating the TGF-ฮฒ1/Smad2/3 pathway
Authors: W. Li, S. Xu, L. Chen, W. Zhang, C. Deng
Journal: Journal of Ethnopharmacology
Year: 2025
Title: Metabolic characteristics of saponins from Panax notoginseng leaves biotransformed by gut microbiota in rats
Authors: J. Liu, L. Shao, J. Zhou, W. Huang
Journal: Analytical Methods
Year: 2025
Title: Hypoglycemic Effect of Ginsenoside Compound K Mediated by N-Acetylserotonin Derived From Gut Microbiota
Authors: S.T.Z. Huang, Y.H. Hu, Y. Gao, W. Zhang, W. Huang
Journal: Phytotherapy Research
Year: 2025
Title: Antitumor potentials of onco-microbial in Chinese patients with pancreatic cancer
Authors: Y. Gao, D. Zhou, Y. Lu, W. Huang, W. Zhang
Journal: Heliyon
Year: 2024
Title: OSGEP regulates islet ฮฒ-cell function by modulating proinsulin translation and maintaining ER stress homeostasis in mice
Authors: Y. Liu, X. Yang, J. Zhou, H. Zhou, Q. Li
Journal: Nature Communications
Year: 2024
Title: Promoting remyelination in central nervous system diseases: Potentials and prospects of natural products and herbal medicine
Authors: H. Zhu, E. Hu, X. Guo, Y. Wang, T. Li
Journal: Pharmacological Research
Year: 2024
Title: Formononetin alleviates no reflow after myocardial ischemia-reperfusion via modulation of gut microbiota to inhibit inflammation
Authors: Y. Zhang, J. Deng, T. Chen, Z. Guo, W. Zhang
Journal: Life Sciences
Year: 2024
Title: Mime: A flexible machine-learning framework to construct and visualize models for clinical characteristics prediction and feature selection
Authors: H. Liu, W. Zhang, Y. Zhang, S.Y. Wanggou, X. Li
Journal: Computational and Structural Biotechnology Journal
Year: 2024